Quick Answer
Quoin Pharmaceuticals, Ltd. reported Research And Development Expense of $9.80 million for the year ending 2025.
- Quoin Pharmaceuticals, Ltd. showed an increase of +172.1% in Research And Development Expense from 2024 to 2025.
- This data is from Quoin Pharmaceuticals, Ltd.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $587.6 thousand | Q2 2022: $726.7 thousand | Q3 2022: $745.5 thousand | Q1 2023: $1.09 million | Q2 2023: $625.1 thousand | Q3 2023: $758.8 thousand | Q1 2024: $885.3 thousand | Q2 2024: $587.5 thousand | Q3 2024: $1.08 million | Q1 2025: $2.37 million | Q2 2025: $2.05 million | Q3 2025: $2.28 million.
- Over the full 11 years of available data (2015 to 2025), Quoin Pharmaceuticals, Ltd.'s Research And Development Expense has grown by 66.3%.
- Historical annual values: Fiscal year 2025: $9.80 million | Fiscal year 2024: $3.60 million | Fiscal year 2023: $3.31 million | Fiscal year 2022: $2.67 million | Fiscal year 2021: $1.56 million | Fiscal year 2020: $244.2 thousand | Fiscal year 2019: $45.7 thousand | Fiscal year 2018: $13.51 million | Fiscal year 2017: -$11.50 million | Fiscal year 2016: $8.26 million | Fiscal year 2015: $5.89 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: